ARCHIVES

Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

NCS Heeds Bloch’s Plea, To Consider Establishing Separate PDQ-Like System For General Public Use

December 7, 1984

New DRCCA Board Skeptical Of CIs renewal, Proposal For Cytopathology

September 26, 1980

Adjuvant BC Therapy Is Topic Of NIH Consensus Conference.

January 28, 2000

Budget Manipulations “Wreaking Havoc,” Korn Tells NCAB; Legal Actions Being Considered

February 13, 1987

NCI, Komen Foundation Fund Summit meeting On Breast Cancer

October 8, 1993

Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response

November 29, 2013